LEADER 03038nam  22005175  450 
001 9910869167603321
005 20260330134420.0
010   $a9783031588112$b(electronic bk.)
010   $z9783031588105
024 7 $a10.1007/978-3-031-58811-2
035   $a(MiAaPQ)EBC31511635
035   $a(Au-PeEL)EBL31511635
035   $a(CKB)32650727800041
035   $a(DE-He213)978-3-031-58811-2
035   $a(EXLCZ)9932650727800041
100   $a20240702d2024      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAlzheimer's Disease and the Eye /$fby Jeffrey N. Weiss
205   $a1st ed. 2024.
210  1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2024.
215   $a1 online resource (146 pages)
300   $aIncludes index.
311 08$aPrint version: Weiss, Jeffrey N. Alzheimer's Disease and the Eye Cham : Springer,c2024 9783031588105 
327   $aPart 1: Introduction -- Chapter 1. Alzheimer's Disease -- Chapter 2. Rates of Dementia -- Chapter 3. Biomarkers and Clinical Endpoints -- Chapter 4. Ocular Biomarkers -- Part 2: Diagnosis -- Chapter 5. Biochemical and Neuroimaging -- Chapter 6. Cognitive Decline -- Chapter 7. EEG/ERP -- Chapter 8. Eye Tracking -- Chapter 9. Light Intervention -- Chapter 10. Retina -- Chapter 11. Tears -- Chapter 12. Telemedicine -- Chapter 13. Virtual Reality -- Part 3: Treatment -- Chapter 14. Recruiting Trials in the US -- Chapter 15. Not Yet Recruiting Trials in the US.
330   $aThis book is a compendium of the worldwide studies of Alzheimer?s disease utilizing the eye as a biomarker, or as a treatment method, that are registered with the United States National Institutes of Health website, clinicaltrials.gov. Clinicaltrials.gov is the largest listing of research studies in the world. The study titles are provided, as is the country of origin and the Clinical Trial Number in order to make it easier for the reader to locate the study and obtain further information. New drug development is costly and time consuming. If through the use of biomarkers, study durations and research costs decrease, there is a greater possibility of a new and effective drug to treat this devastating disease. The eye offers the possibility of early diagnosis and of treatment. Alzheimer?s Disease and the Eye is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
606   $aOphthalmology
606   $aOphthalmology
606   $aMalaltia d'Alzheimer$2thub
606   $aOftalmologia$2thub
608   $aLlibres electrònics$2thub
615  0$aOphthalmology.
615 14$aOphthalmology.
615  7$aMalaltia d'Alzheimer
615  7$aOftalmologia
676   $a616.83106515
700   $aWeiss$b Jeffrey N.$0927848
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
912   $a9910869167603321
996   $aAlzheimer's Disease and the Eye$94171676
997   $aUNINA